miR-124 Activator
Autoimmune Diseases
Phase 2Active
Key Facts
About Formation Bio
Formation Bio is a private, pre-revenue biotech company positioning itself as the 'pharma company of the future.' It operates a unique business model focused on in-licensing clinical-stage drug candidates and advancing them through development using an integrated AI and technology platform designed to improve decision-making, trial design, and operational efficiency. The company aims to bridge the gap between the rapid pace of drug discovery and the slow, costly traditional development process, with an initial program targeting autoimmune diseases via a miR-124 activator.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Gavocabtagene autoleucel | astellas | Phase 1/2 |
| TYK-101 | TYK Medicines | Phase 1 |
| HCB206 | HanchorBio | Preclinical |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |